Mark Leiser is the Editorial Director for Healio, a platform that provides healthcare professionals with news, information, and education. With a focus on medical advancements and breakthroughs, Mark's articles cover a wide range of topics including cancer therapies, clinical trials, and emerging treatments.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Mark's coverage indicates a strong focus on healthcare and pharmaceuticals, particularly in the context of clinical trial data and scientific breakthroughs. He is most likely to be interested in pitches that provide access to exclusive data or insights related to new treatments for cancer, hemophilia, gene therapy, or other significant medical advancements.
Given Mark’s reliance on citing data, he may respond well to expert sources who can offer detailed analysis of clinical trial results or scientific developments in the mentioned fields. Pitches should emphasize the depth of expertise and ability to provide unique perspectives based on robust evidence.
It is important for potential contributors reaching out to Mark Leiser with relevant information regarding recent discoveries or groundbreaking research within these specialized areas.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Bhavna Bhasin-Chhabr, Mark Leiser
Acute kidney injury is a frequent complication following hematopoietic cell transplantation.
The FDA expanded the approval of dostarlimab-gxly for treatment of endometrial cancer.
The FDA granted accelerated approval to afamitresgene autoleucel for certain adults with unresectable or metastatic synovial sarcoma.
The FDA approved vorasidenib for certain patients with astrocytoma or oligodendroglioma.The indication applies to use of the agent by adults or children aged 12 years or older with grade 2 disease and a susceptible isocitrate dehydrogenase (IDH) 1 or 2 mutation after surgery.
By: Mindy Valcarcel, Mark Leiser
The FDA expanded the approval of durvalumab for lung cancer. The new indication applies to use of the agent with platinum-containing
By: Mark Leiser, Mindy Valcarcel
The addition of tafasitamab-cxix to lenalidomide and rituximab improved outcomes for patients with relapsed or refractory follicular lymphoma, according to the agent's manufacturer.
By: Mark Leiser, Mindy Valcarcel
Cognition appeared associated with likelihood that individuals would return to work 2 years after breast cancer diagnosis, according to results of a case series study.
By: Mark Leiser, Mindy Valcarcel
Ann H. Partridge, MD, MPH, will receive this year's ESMO Award.
By: Mindy Valcarcel, Mark Leiser
The addition of retifanlimab to standard first-line chemotherapy improved outcomes for certain patients with advanced squamous cell carcinoma of the anal canal, according to randomized phase 3 study results presented at ESMO Congress.
By: Mindy Valcarcel, Mark Leiser
The addition of lenvatinib and pembrolizumab to transarterial chemoembolization extended PFS for patients with intermediate-stage hepatocellular carcinoma, according to randomized phase 3 study results.
(833) 317-6278 
